Gene therapy legend R. Jude Samulski, Ph.D., co-founder and chief scientific officer of Asklepios BioPharmaceutical (AskBio) since the company was established in 2001, is leaving the CSO job but remaining on the company board.AskBio announced that Mansuo Shannon, Ph.D., becomes CSO effective today. Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, where she also served as CSO.
A recent article published earlier this month in Frontier in Cellular and Infection Microbiology, recognized R. Jude Samulski, Ph.D., as the most cited and co-cited expert for AAV gene therapy advancements. Here are the details.
A recent article, “Bibliometric analysis of global research trends in adeno-associated virus vector for gene therapy (1991-2022),” published earlier this month in Frontier in Cellular and Infection Microbiology, recognized R. Jude Samulski, Ph.D., as the most cited and co-cited expert for AAV gene therapy advancements.